Peter Horn Møller
Peter has a scientific background with a master in biochemistry and organic chemistry and a PhD in medical sciences.20 years of industrial experience, first as a patent attorney and later as corporate responsible for IP strategy and licensing, has given Peter a solid track record of turning state-of-the-art science into great, intellectually protected products.
Peter is a strong believer in realizing own strengths and weaknesses and has a formidable intuition enabling him to find people of complementary skills. The ability to assess the scientific founders and then supplement with lacking competences is one of the central pillars that Marigold is built on.
Confidence and trust from business partners and scientists are key to Peter. He has an altruistic and holistic approach to his mission, but always with sharp focus on the goal - to bring promising technologies from the laboratory to the patients. He is recognized for his interpersonal and communicative skills, enabling him to work equally well with scientists and venture capitalists.
Through his career, Peter has drafted and prosecuted numerous patent applications for Scandinavian universities, academic based spinouts as well as established biotech and large pharma companies. His combination of interdisciplinary knowledge on biotechnology, IP and legal requirements gives him an instrumental ability to see the path from early research to commercial launch.
Peter’s career started as a patent attorney, where he became manager for the life-science and chemistry department and later partner and COO in one of the major European patent law firms. Later, and charged with a keen interest in applying his IP skills in business creation, Peter joined a partnership of senior biotech executives in establishing biotech companies, and had an interim C-level role in a Norwegian Biobank.
Prior to founding Marigold Innovation, Peter was part of the global management group of Novozymes IP department, and member of a Novozymes’ management group for strategic IP and licensing. He had a key role in the spin-out of Albumedix from Novozymes.
Peter has been an invited member of the US-based think-tank, The Gathering 2.0, which focus on future trends in strategic IP and licensing.
Based on his understanding of the challenges, requirements and processes to transform early concepts into viable companies, Peter decided to follow his passion and founded Marigold Innovation in 2018.